A5066861614- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Lung Cancer Research Studies
- RNA modifications and cancer
- Computational Drug Discovery Methods
- Colorectal Cancer Treatments and Studies
- MicroRNA in disease regulation
- Ferroptosis and cancer prognosis
- Immunotherapy and Immune Responses
- Extracellular vesicles in disease
- CAR-T cell therapy research
- Gastric Cancer Management and Outcomes
- AI in cancer detection
- Epigenetics and DNA Methylation
- Cancer Research and Treatments
- Cancer therapeutics and mechanisms
- Advanced X-ray and CT Imaging
- Melanoma and MAPK Pathways
- Esophageal Cancer Research and Treatment
- Medical Imaging Techniques and Applications
- Immune Cell Function and Interaction
- Cancer Cells and Metastasis
NYU Langone Health
2019-2024
NYU Langone’s Laura and Isaac Perlmutter Cancer Center
2019-2024
New York University
2019-2024
Cleveland Clinic
2013-2022
Sanjay Gandhi Post Graduate Institute of Medical Sciences
2022
Hinge Health
2022
Case Western Reserve University
2017-2019
Memorial Sloan Kettering Cancer Center
2019
New York Oncology Hematology
2019
Cleveland Foundation
2018
Sotorasib showed anticancer activity in patients with KRAS p.G12C–mutated advanced solid tumors a phase 1 study, and particularly promising was observed subgroup of non–small-cell lung cancer (NSCLC).
<h3>Importance</h3> Early-phase trials with monoclonal antibodies targeting PD-1 (programmed cell death protein 1) and PD-L1 1 ligand have demonstrated durable clinical responses in patients non–small-cell lung cancer (NSCLC). However, current assays for the prognostic and/or predictive role of tumor expression are not standardized respect to either quantity or distribution expression. <h3>Objective</h3> To demonstrate NSCLC tumors using both conventional immunohistochemistry (IHC)...
RET fusions are oncogenic drivers in 1 to 2% of non-small-cell lung cancers (NSCLCs). In patients with fusion-positive NSCLC, the efficacy and safety selective inhibition unknown.We enrolled advanced NSCLC who had previously received platinum-based chemotherapy those were untreated separately a phase 1-2 trial selpercatinib. The primary end point was an objective response (a complete or partial response) as determined by independent review committee. Secondary points included duration...
Blockade of the PD-1/PD-L1 axis emerged as a promising new therapeutic option for cancer that has resulted in lasting responses metastatic renal, lung carcinomas, and melanomas. Tumor PD-L1 protein expression may predict response to drugs targeting this pathway. Measurement is limited by lack standardized immunohistochemical methods variable performance antibodies. Our goal was correlate mRNA with clinical variables primary breast carcinomas.The fluorescent RNAscope paired-primer assay used...
BackgroundAlterations involving the RET kinase are implicated in pathogenesis of lung, thyroid and other cancers. However, clinical activity multikinase inhibitors (MKIs) with anti-RET RET-altered patients appears limited, calling into question therapeutic potential targeting RET. LOXO-292 is a selective inhibitor designed to inhibit diverse fusions, activating mutations acquired resistance mutations.Patients methodsPotent activity, high selectivity, central nervous system coverage were...
Purpose In addition to prospective trials for non–small-cell lung cancers (NSCLCs) that are driven by less common genomic alterations, registries provide complementary information on patient response targeted therapies. Here, we present the results of an international registry patients with RET-rearranged NSCLCs, providing largest data set, our knowledge, outcomes RET-directed therapy thus far. Methods A global, multicenter network thoracic oncologists identified pathologically confirmed...
Purpose To evaluate ability of radiomic (computer-extracted imaging) features to distinguish non-small cell lung cancer adenocarcinomas from granulomas at noncontrast CT. Materials and Methods For this retrospective study, screening or standard diagnostic CT images were collected for 290 patients (mean age, 68 years; range, 18–92 125 men [mean 67 18–90 years] 165 women 33–92 years]) two institutions between 2007 2013. Histopathologic analysis was available one nodule per patient....
Abstract Purpose: To determine the tumor tissue/cell distribution, functional associations, and clinical significance of PD-1, LAG-3, TIM-3 protein expression in human non–small cell lung cancer (NSCLC). Experimental Design: Using multiplexed quantitative immunofluorescence, we performed localized measurements CD3, &gt;800 clinically annotated NSCLCs from three independent cohorts represented tissue microarrays. Associations between marker's major genomic alterations were studied The...
No predictive biomarkers can robustly identify patients with non-small cell lung cancer (NSCLC) who will benefit from immune checkpoint inhibitor (ICI) therapies. Here, in a machine learning setting, we compared changes ("delta") the radiomic texture (DelRADx) of CT patterns both within and outside tumor nodules before after two to three cycles ICI therapy. We found that DelRADx could predict response therapy overall survival (OS) for NSCLC. retrospectively analyzed data acquired 139 NSCLC...
The presence of a high degree tumor-infiltrating lymphocytes (TIL) has been proven to be associated with outcome in patients non-small cell lung cancer (NSCLC). However, recent evidence indicates that tissue architecture is also prognostic disease-specific survival and recurrence. We show set descriptors (spatial TIL, SpaTIL) capture density, spatial colocalization TILs tumor cells across digital images can predict likelihood recurrence early-stage NSCLC.The association between NSCLC SpaTIL...
In ret proto-oncogene (RET)-rearranged lung cancers, data on the frequency of brain metastases and, in particular, outcomes multikinase inhibitor therapy patients with intracranial disease are not well characterized.A global, multi-institutional registry (cohort A, n = 114) and a bi-institutional set B, 71) RET-rearranged cancer were analyzed. Patients eligible if they had stage IV cancers harboring RET rearrangement by local testing. The incidence determined.The at time diagnosis was 25%...
Immunotherapy of cancer with checkpoint inhibitors has been associated a spectrum autoimmune and systemic inflammatory reactions known as immune-related adverse events (irAEs). Rheumatic irAEs are infrequently reported extensively described. Here, we report our experience over an 18-month period 15 patients evaluated in the rheumatology department for rheumatic irAEs. We identified 13 without pre-existing disease (AID) who subsequently developed irAEs, two established AID referred...
Purpose: Determine the localized expression pattern and clinical significance of VISTA/PD-1H in human non-small cell lung cancer (NSCLC).Experimental Design: Using multiplex quantitative immunofluorescence (QIF), we performed measurements VISTA, PD-1, PD-L1 protein 758 stage I-IV NSCLCs from 3 independent cohorts represented tissue microarray format. The targets were selectively measured cytokeratin+ tumor epithelial cells, CD3+ T CD4+ T-helper CD8+ cytotoxic CD20+ B lymphocytes CD68+...
To determine the expression level, associations, and biological role of PD-L1, IDO-1, B7-H4 in non-small cell lung cancer (NSCLC).Using multiplexed quantitative immunofluorescence (QIF), we measured levels B7-H4, different tumor-infiltrating lymphoycte (TIL) subsets 552 stages I-IV carcinomas from two independent populations. Associations between marker levels, TILs, major clinicopathologic variables were determined. Validation findings was performed using mRNA data The Cancer Genome Atlas...
Abstract Despite substantial progress in lung cancer immunotherapy, the overall response rate patients with KRAS-mutant adenocarcinoma (LUAD) remains low. Combining standard immunotherapy adjuvant approaches that enhance adaptive immune responses—such as epigenetic modulation of antitumor immunity—is therefore an attractive strategy. To identify regulators tumor immunity, we constructed epigenetic-focused single guide RNA library and performed vivo CRISPR screen a KrasG12D/Trp53−/− LUAD...